GeNeuro SA (GNRO.PA)

EUR 0.08

(6.38%)

Total Liabilities Summary of GeNeuro SA

  • GeNeuro SA's latest annual total liabilities in 2023 was 20.13 Million EUR , up 101.26% from previous year.
  • GeNeuro SA's latest quarterly total liabilities in 2023 FY was 20.13 Million EUR , up 101.26% from previous quarter.
  • GeNeuro SA reported annual total liabilities of 10 Million EUR in 2022, up 30.05% from previous year.
  • GeNeuro SA reported annual total liabilities of 7.69 Million EUR in 2021, up 54.0% from previous year.
  • GeNeuro SA reported quarterly total liabilities of 20.13 Million EUR for 2023 Q4, down 0.0% from previous quarter.
  • GeNeuro SA reported quarterly total liabilities of 17.79 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of GeNeuro SA (2023 - 2013)

Historical Annual Total Liabilities of GeNeuro SA (2023 - 2013)

Year Total Liabilities Total Liabilities Growth
2023 20.13 Million EUR 101.26%
2022 10 Million EUR 30.05%
2021 7.69 Million EUR 54.0%
2020 4.99 Million EUR -65.8%
2019 14.6 Million EUR 171811.08%
2018 8497.30 EUR -50.92%
2017 17.31 Thousand EUR -9.42%
2016 19.11 Thousand EUR 0.23%
2015 19.06 Thousand EUR -99.32%
2014 2.81 Million EUR 89.33%
2013 1.48 Million EUR 0.0%

Peer Total Liabilities Comparison of GeNeuro SA

Name Total Liabilities Total Liabilities Difference
ABIONYX Pharma SA 6.91 Million EUR -191.376%
ABIVAX Société Anonyme 131.05 Million EUR 84.632%
Adocia SA 31.87 Million EUR 36.806%
Aelis Farma SA 13.08 Million EUR -53.975%
Biophytis S.A. 15.84 Million EUR -27.074%
Advicenne S.A. 24.37 Million EUR 17.382%
genOway Société anonyme 14.45 Million EUR -39.285%
IntegraGen SA 5.97 Million EUR -236.799%
Medesis Pharma S.A. 6.42 Million EUR -213.404%
Neovacs S.A. 3.71 Million EUR -442.544%
NFL Biosciences SA 3.62 Million EUR -456.246%
Plant Advanced Technologies SA 6.78 Million EUR -196.946%
Quantum Genomics Société Anonyme 3.31 Million EUR -508.437%
Sensorion SA 13.22 Million EUR -52.26%
Theranexus Société Anonyme 5.01 Million EUR -301.498%
TME Pharma N.V. 2.78 Million EUR -623.156%
Valbiotis SA 13.7 Million EUR -46.921%
TheraVet SA 1.48 Million EUR -1256.229%
Valerio Therapeutics Société anonyme 20.46 Million EUR 1.603%
argenx SE 402.79 Million EUR 95.0%
BioSenic S.A. 32.26 Million EUR 37.578%
Celyad Oncology SA 9.97 Million EUR -101.843%
DBV Technologies S.A. 38.74 Million USD 48.02%
Galapagos NV 1.56 Billion EUR 98.71%
Genfit S.A. 105.92 Million EUR 80.986%
Hyloris Pharmaceuticals SA 8.61 Million EUR -133.859%
Innate Pharma S.A. 132.29 Million EUR 84.776%
Inventiva S.A. 101.59 Million EUR 80.176%
MaaT Pharma SA 22.46 Million EUR 10.35%
MedinCell S.A. 77.77 Million EUR 74.103%
Nanobiotix S.A. 95.74 Million EUR 78.964%
Onward Medical N.V. 25.69 Million EUR 21.629%
Oryzon Genomics S.A. 25.12 Million EUR 19.843%
OSE Immunotherapeutics SA 59.07 Million EUR 65.91%
Oxurion NV 19.73 Million EUR -2.047%
Pharming Group N.V. 228.28 Million EUR 91.178%
Poxel S.A. 53.9 Million EUR 62.635%
GenSight Biologics S.A. 34.72 Million EUR 42.005%
Transgene SA 26.51 Million EUR 24.049%
Financière de Tubize SA 123.65 Million EUR 83.712%
UCB SA 6.56 Billion EUR 99.693%
Valneva SE 341.14 Million EUR 94.096%
Vivoryon Therapeutics N.V. 4.54 Million EUR -342.927%